Some countries move to limit Ozempic supply to patients amid rampant demand for resales

Novo Nordisk, the pharmaceutical company that makes Ozempic, is encountering supply challenges. Photo: Getty Images.

Louise Breusch Rasmussen

Doctors in Denmark should limit how many packs of Novo Nordisk's Ozempic diabetes drug patients can pick up at one time, the Danish Patient Safety Authority said on Monday, amid worries that some may acquire a larger supply than needed.

Neighbouring Norway meanwhile said it would tighten restrictions on the use of Ozempic, requiring doctors to seek cost reimbursements on behalf of each individual patient rather than an automatic coverage for all users.

Latest NewsMore